The study was supported by untied educational grants from Mundipharma; research fellowships from the National Health and Medical Research Council (NHMRC); and the Australian Government under the Substance Misuse Prevention and Service Improvements Grant Fund.
Several investigators report receiving untied educational grants from Reckitt Benckiser.
TRENDING ON CPA: Equalizing The Pain Pendulum
Mundipharma and Reckitt Benckiser are both makers of abuse-deterrent opioid formulations.
1. OxyContin tamper-resistant oxycodone tablets. Drugs and Poisons Regulation, April 2015. From the department of health and human services, state government of Victoria, Australia. Available at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&ved=0CCwQFjACahUKEwiQ3sGU59HIAhUE_WMKHRmwBe4&url=https%3A%2F%2Fwww2.health.vic.gov.au%2FApi%2Fdownloadmedia%2F%257B30745BB2-5BA2-4464-966D-F0D0608A453E%257D&usg=AFQjCNGmB86Ml6qLOZXEZRe_afcUwARf7w&bvm=bv.105454873,d.cGc. Accessed: October 20, 2015
2. Degenhardt L, Bruno R, Ali R, Lintzeris N, Farrell M, Larance, B. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. Drug and Alcohol Dependence. 2015; 151: 56-67. doi:10.1016/j.drugalcdep.2015.02.038
3. Larance B, Lintzeris N, Bruno R et al. The characteristics of a cohort who tamper with prescribed and diverted opioid medications. Journal of Substance Abuse. 2015; 58: 51-61. doi:10.1016/j.jsat.2015.06.001